var data={"title":"Chenodeoxycholic acid (chenodiol): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Chenodeoxycholic acid (chenodiol): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7593?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=chenodeoxycholic-acid-chenodiol-drug-information\" class=\"drug drug_general\">see &quot;Chenodeoxycholic acid (chenodiol): Drug information&quot;</a> and <a href=\"topic.htm?path=chenodeoxycholic-acid-chenodiol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Chenodeoxycholic acid (chenodiol): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46233250\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because of the potential hepatotoxicity of chenodiol, poor response rate in some subgroups of chenodiol treated patients, and an increased rate of a need of cholecystectomy in other chenodiol treated subgroups, chenodiol is not an appropriate treatment for many patients with gallstones. Chenodiol should be reserved for carefully selected patients and treatment must be accompanied by systematic monitoring for liver function alterations. Aspects of patient selection, response rates and risks versus benefits are given in the insert.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10484405\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Chenodal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F988036\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Bile Acid</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F988046\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=chenodeoxycholic-acid-chenodiol-drug-information\" class=\"drug drug_general\">see &quot;Chenodeoxycholic acid (chenodiol): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gallstone dissolution:</b> Limited data available: Oral: Children &ge;12 years and Adolescents: 15 mg/kg/day divided 3 times daily with meals; dosing based on reported experience in three obese pediatric patients (age range: 12 to 13 years); <b>Note:</b> Not first-line therapy due to frequent side effect (increased LFT, diarrhea) and other therapeutic options available (Podda 1982) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b> Inborn errors of bile acid biosynthesis:</b>  Very limited data available: Oral: Infants, Children and Adolescents: <b>Note:</b> Due to the rarity of the disease states, data is limited to small case series and case reports. Adjust dose based upon targeted bile acid or biosynthesis intermediate compound concentrations. Combination therapy with ursodeoxycholic acid (urosdiol) dependent on specific deficiency, and phenotypic presentation of syndrome. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cerebrotendinous xanthomatosis:</i> Initial: 10 to 15 mg/kg/day divided 1 to 3 times daily; in adolescents, a fixed dose of 750 mg/day has also been reported (Beringer 2010; Kaufman 2012; Setchell 2006; van Heijst 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Steroid dehydrogenase or reductase deficiencies (susceptible):</i> Usual initial range:  5 to 10 mg/kg/day divided once or twice daily; higher initial doses of 11 to 18 mg/kg/day have also been reported; a maintenance dose of 5 mg/kg/day was the most frequently reported and initiated once targeted bile acid normalized or stabilized (depending upon the syndrome) (Clayton 1996; Clayton 2011; Ichimiya 1990; Riello 2010) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Peroxisome deficiency, including Zellweger syndrome:</i> Oral: 100 to 250 mg/day or 5 mg/kg/day have been used (Maeda 2002; Setchell \t1992)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Gallstone dissolution (monotherapy):</b> Oral: Initial: 250 mg twice daily for the first 2 weeks and increasing by 250 mg/day each week thereafter until the recommended or maximum tolerated dose is achieved; maintenance: 13 to 16 mg/kg/day in 2 divided doses. <b>Note:</b> Dosages &lt;10 mg/kg are usually ineffective and may increase the risk of cholecystectomy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Use extreme caution; contraindicated for use in presence of known hepatocyte dysfunction or bile duct abnormalities.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F240027\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chenodal: 250 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F240012\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22460185\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Prescriptions are only dispensed by Dohmen Life Science Services Chenodal Total Care Program which may be contacted at 866-758-7068.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22368801\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">May be taken without  regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10484459\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 20&deg;C (68&deg;F to 77&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F988037\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Oral dissolution of radiolucent cholesterol gallstones in well-opacifying gallbladders in patients who are not candidates for surgery due to systemic disease or age (FDA approved in adults); has also been used for lipid storage diseases, including cerebrotendinous xanthomatosis, Zellweger syndrome, and other susceptible bile acid biosynthesis defects which result in low chenodeoxycholic acid concentrations </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10484411\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Increased LDL cholesterol, increased serum cholesterol (total)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Diarrhea (30% to 40%; severe diarrhea that requires dose reduction: 10% to 15%), biliary colic,* abdominal cramps, abdominal pain, anorexia, constipation, dyspepsia, flatulence, heartburn, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Leukopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased serum transaminases (&ge;30%; &gt;3 x ULN: 2% to 3%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F240030\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known hepatocyte dysfunction or bile ductal abnormalities (eg, intrahepatic cholestasis, primary biliary cirrhosis, sclerosing cholangitis); use in a patient with a gallbladder confirmed as nonvisualizing after two consecutive single doses of dye; radiopaque stones; gallstone complications or compelling reasons for gallbladder surgery (eg, unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, biliary gastrointestinal fistula); use in pregnancy or in women who can become pregnant.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F240017\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diarrhea: Dose-related diarrhea commonly occurs (up to 40% of patients); may occur at any time, but is most common during treatment initiation. Diarrhea is usually mild and does not interfere with therapy; however, diarrhea may be severe and a temporary dosage reduction or discontinuation may be required. Antidiarrheal agents may be of benefit in some patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Drug-induced liver toxicity may occur (dose-related); close monitoring of serum aminotransferase levels recommended during therapy. Aminotransferase elevations &gt;3 times ULN have been reported; prompt discontinuation of therapy recommended. Transaminase levels usually return to normal after chenodiol is withheld. Temporarily withhold therapy for transient transaminase elevations of 1.5 to 3 times ULN. Biochemical and histologic chronic active hepatitis has been reported (rare case reports), although a causal relationship to chenodiol could not be determined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Colon cancer: Epidemiologic studies have suggested that bile acids may increase the risk of colon cancer. Evidence is weak and conflicting; however, a potential link between bile acids and colon cancer cannot be ruled out.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Avoid use in patients with preexisting hepatic impairment or elevated liver enzymes; use contraindicated in patients with known hepatocyte dysfunction or bile ductal abnormalities.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <b> [US Boxed Warning]: Due to the hepatotoxicity potential, poor response rate in certain subgroups, and an increased rate of cholecystectomy necessary in other subgroups, chenodiol is not an appropriate treatment for many patients with gallstones. Use should be reserved to carefully selected patients; treatment must be accompanied with liver function monitoring.</b> Studies have shown dissolution rates are higher in patients with small (&lt;15 mm in diameter), radiolucent, and/or floatable stones. Radiopaque (calcified or partially calcified) stones and bile pigment stones do not respond to bile acid dissolution therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Duration of therapy: Response to therapy should be monitored with oral cholecystograms or ultrasonograms at 6- to 9-month intervals. Complete dissolution should then be confirmed by a repeat test 1 to 3 months after continued therapy. If partial dissolution is not observed by 9 to 12 months, complete dissolution is unlikely. If no response is observed by 18 months, therapy should be discontinued; safety beyond 24 months of use has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gallstone recurrence: May occur within 5 years in approximately 50% of patients; serial cholecystograms or ultrasonograms are recommended to monitor for recurrence. Prophylactic doses have not been established and reduced doses cannot be recommended. Long-term consequences of repeated courses or chenodiol are not known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299012\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F240021\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=91296&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aluminum Hydroxide: May decrease the serum concentration of Chenodiol. Management: Consider administration of chenodiol 2 hours before or 6 hours after aluminum-containing antacid products to prevent adsorption in the gastrointestinal tract.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Chenodiol. Management: Administration of chenodiol 5 hours or more after bile acid sequestrants may reduce chenodiol adsorption in the gastrointestinal tract.  Monitor for decreased therapeutic effects of chenodiol in patients receiving bile acid sequestrants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the therapeutic effect of Chenodiol. Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fibric Acid Derivatives: May diminish the therapeutic effect of Chenodiol. Management: Monitor clinical response to chenodiol closely when used together with any fibric acid derivative.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Chenodiol may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F240023\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10484407\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated in women who are or can become pregnant. Adverse events were observed in some animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F988047\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum aminotransferase levels (monthly for first 3 months, then every 3 months during therapy); serum cholesterol (every 6 months); for gallstone dissolution: Oral cholecystograms and/or ultrasonograms (6-9 month intervals for response to therapy); dissolutions of stones should be confirmed 1-3 months later; for bile acid biosynthesis defects: Targeted bile acids or intermediate product concentrations from either serum or blood should be measured (as appropriate) (Clatyon 2011; Setchell, 2006)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F240015\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Chenodiol (chenodeoxycholic acid) is a naturally occurring human bile acid, normally constituting one-third of the total bile acid pool. In patients with cholesterol gallstones, chenodiol is believed to suppress hepatic synthesis of cholesterol and cholic acid, and inhibit biliary cholesterol secretion, which leads to increased production of cholesterol unsaturated bile thereby allowing for dissolution of gallstones. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10484414\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid, almost completely absorbed in proximal small intestine (Crosignani 1996) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: ~1600 L (Crosignani 1996) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Converted hepatically to taurine and glycine conjugates and secreted in bile; extensive first-pass hepatic clearance; undergoes enterohepatic circulation; further metabolized in colon by bacteria to lithocholic acid; small portion of lithocholate is absorbed and converted to sulfolithocholyl conjugates in the liver</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life: ~45 hours (Crosignani 1996) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (~80%, as lithocholate) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321898\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Chenodal Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $56,760.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539772\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aylehning (TW);</li>\n      <li>Chebil (PT);</li>\n      <li>Chendol (GB, MY, PT);</li>\n      <li>Cheno (TW);</li>\n      <li>Chenofalk (AT, BE, CH, CZ, DE, GB, HK, HN, ID, IT, MY, NL, PH);</li>\n      <li>Chenossil (IT);</li>\n      <li>Quenobilan (ES);</li>\n      <li>Theramatic (GR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Beringer VM, Gross B, Morad K, etal. Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat. <i>Pediatrics</i>. 2010;123:143-147.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-pediatric-drug-information/abstract-text/19117873/pubmed\" target=\"_blank\" id=\"19117873\">19117873</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clayton PT. Disorders of bile acid synthesis. <i>J Inherit Meab Dis</i>. 2011;34 593-604.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-pediatric-drug-information/abstract-text/21229319/pubmed\" target=\"_blank\" id=\"21229319\">21229319</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clayton PT, Mills KA, Johnson AW, et al. Delta 4-3-oxosteroid 5&szlig;-reductase deficiency: failure of ursodeoxycholic acid treatment and response to chenodeoxycholic acid plus cholic acid. <i>Gut</i>. 1996;38:623-628.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-pediatric-drug-information/abstract-text/8707100/pubmed\" target=\"_blank\" id=\"8707100\">8707100</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crosignani A, Setchell KDR, Invernizzi P, etal. Clinical pharmacokinetics of therapeutic bile acids. <i>Clin Pharmacokineti</i>. 1996;30(5):333-358.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-pediatric-drug-information/abstract-text/8743334/pubmed\" target=\"_blank\" id=\"8743334\">8743334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ichimiya H, Nazer H, Gunasekaran T, et al. Treatment of chronic liver disease caused by 3&szlig;-hydroxy-&#8710;5-C27-steroid dehydrogenase deficiency with chenodeoxycholic acid. <i>Archives of Disease in Childhood</i>. 1990;65:1121-1124.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-pediatric-drug-information/abstract-text/2248502/pubmed\" target=\"_blank\" id=\"2248502\">2248502</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaufman MA, Gonzalez-Moron D, Consalvo D, et al. Cerebrotendinous xanthomatosis revealed in drug-resistant epilepsy diagnostic workup. <i>Am J Med Sci</i>. 2012;343(4):332-333.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-pediatric-drug-information/abstract-text/22197981/pubmed\" target=\"_blank\" id=\"22197981\">22197981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maeda K, Kimura A, Yamoto Y, et al. Oral bile acid treatment in two Japanese patients with Zellweger syndrome. <i>Journal of Pediatric Gastroenterology and Nutrition</i>. 2002;35:227-230.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-pediatric-drug-information/abstract-text/12187304/pubmed\" target=\"_blank\" id=\"12187304\">12187304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Podda M, Zuin M, Dioguardi ML, et al. Successful treatment of gallstones with bile acids in obese adolescents. <i>Arch Dis Child</i>. 1982;57(12):956-958.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-pediatric-drug-information/abstract-text/7181529/pubmed\" target=\"_blank\" id=\"7181529\">7181529</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riello L, Antiga LD, Guido M, et al. Titration of bile acid supplements in 3&szlig;-hydroxy-&#8710;5-C27-steroid dehydrogenase/isomerase deficiency. <i>JPGN</i>. 2010;50:655-660.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-pediatric-drug-information/abstract-text/20400917/pubmed\" target=\"_blank\" id=\"20400917\">20400917</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Setchell KD, Bragetti P, Zimmer-Nechemias L, et al. Oral bile acid treatment and the patient with Zellweger syndrome. <i>Hepatology</i>. 1992;15(2):198-207. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Setchell KDR, Heubi JE. Defects in bile acid biosynthesis &ndash; diagnosis and treatment. <i>Journal of Pediatric Gastroenterology and Nutrition</i>. 2006;43:17-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-pediatric-drug-information/abstract-text/16819396/pubmed\" target=\"_blank\" id=\"16819396\">16819396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Heijst AJ, Verrips A, Wevers RA, et al. Treatment and follow-up of children with cerebrotendinous xanthomatosis. <i>Eur J Pediatr</i>. 1998;157(4):313-316.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-pediatric-drug-information/abstract-text/9578968/pubmed\" target=\"_blank\" id=\"9578968\">9578968</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 91296 Version 33.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F46233250\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F10484405\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F988036\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F988046\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F240027\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F240012\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F22460185\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F22368801\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F10484459\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F988037\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F10484411\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F240030\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F240017\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299012\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F240021\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F240023\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F10484407\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F988047\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F240015\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F10484414\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16321898\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539772\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/91296|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=chenodeoxycholic-acid-chenodiol-drug-information\" class=\"drug drug_general\">Chenodeoxycholic acid (chenodiol): Drug information</a></li><li><a href=\"topic.htm?path=chenodeoxycholic-acid-chenodiol-patient-drug-information\" class=\"drug drug_patient\">Chenodeoxycholic acid (chenodiol): Patient drug information</a></li></ul></div></div>","javascript":null}